Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: The Glasgow Microenvironment Score (GMS) combines peritumoural inflammation and tumour stroma percentage to assess interactions between tumour and microenvironment. This was previously demonstrated to associate with colorectal cancer (CRC) prognosis, and now requires validation and assessment of interactions with adjuvant therapy. METHODS: Two cohorts were utilised; 862 TNM I-III CRC validation cohort, and 2912 TNM II-III CRC adjuvant chemotherapy cohort (TransSCOT). Primary endpoints were disease-free survival (DFS) and relapse-free survival (RFS). Exploratory endpoint was adjuvant chemotherapy interaction. RESULTS: GMS independently associated with DFS (p = 0.001) and RFS (p 

Original publication




Journal article


Br J Cancer

Publication Date





786 - 796


Aged, Antineoplastic Combined Chemotherapy Protocols, Capecitabine, Chemotherapy, Adjuvant, Cohort Studies, Colorectal Neoplasms, Disease-Free Survival, Female, Fluorouracil, Humans, Kaplan-Meier Estimate, Leucovorin, Male, Middle Aged, Neoplasm Staging, Organoplatinum Compounds, Oxaliplatin, Prognosis, Reproducibility of Results, Tumor Microenvironment